Johansen, Odd Erik

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 3,655

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,329

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,084

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial

Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 907

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 740

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

Rosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., et al. (2019) · JAMA

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 612

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 507

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology

Cardiovascular Health and Disease PreventionDiabetes Treatment and Management

Cited by 470

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 243

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 242

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA ® )

Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 212

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 168

Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA

McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 164

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Zinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Fitchett, D., Kohler, S., Mattheus, M., Woerle, H. J., Broedl, U. C., Johansen, O. E., et al. (2017) · Stroke

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 136

Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication

Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 128

The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial

Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementObstructive Sleep Apnea Research

Cited by 93

Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial

Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 62

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial

Fitchett, D., Inzucchi, S. E., Wanner, C., Mattheus, M., George, J. T., Vedin, O., Zinman, B., & Johansen, O. E. (2020) · European Heart Journal

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 34

The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study

Ard, J. D., Neeland, I. J., Rothberg, A. E., Chilton, R. J., de Luis, D., Cohen, S. S., & Johansen, O. E. (2024) · Diabetes, Obesity and Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsBariatric Surgery and Outcomes

Cited by 12

Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects

Kushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 5

549-P: A Premeal Drink of Low-Dose Whey Protein (WP) Microgel Rapidly Increases Bioavailability of Branched Chain Amino Acids (BCAA) in People with Type 2 Diabetes (T2D) : A Randomized, Placebo-Controlled Crossover Study

NEELAND, I., AHRÉN, B., CORTHÉSY, J. V., GRZYWINSKI, Y., MAGOS, Z., VON EYNATTEN, M., & JOHANSEN, O. E. (2022) · Diabetes

Muscle metabolism and nutritionDiabetes Treatment and Management

Cited by 2